Normally the big pharma partner pays 100% of the P3 trials cost. RAC would supply only the drug and technical advice.
You're correct re the partnership being negotiated after P2 but before P3.
Yes there is significant derisking for a P3 drug. Which IMO is when any buyout of remaining milestones and royalties should be negotiated. The derisking would achieve a higher buyout value.
General Comments / Chat, page-2691
-
- There are more pages in this discussion • 8,558 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.040(2.93%) |
Mkt cap ! $239.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.50 | $1.35 | $167.2K | 118.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3547 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 2072 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |